國立高雄大學圖資館 |

Circulating tumor cellsadvances in liquid biopsy technologies /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Circulating tumor cellsedited by Richard J. Cote, Evi Lianidou.
Reminder of title:	advances in liquid biopsy technologies /
other author:	Cote, Richard J.
Published:	Cham :Springer International Publishing :2023.
Description:	xxi, 668 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
Subject:	Cancer cellsHandbooks, manuals, etc.
Online resource:	https://doi.org/10.1007/978-3-031-22903-9
ISBN:	9783031229039$q(electronic bk.)

Circulating tumor cellsadvances in liquid biopsy technologies /
Circulating tumor cellsadvances in liquid biopsy technologies /[electronic resource] :edited by Richard J. Cote, Evi Lianidou. - Second edition. - Cham :Springer International Publishing :2023. - xxi, 668 p. :ill., digital ;24 cm. - Current cancer research,2199-2592. - Current cancer research..

Part 1. CTC Technologies -- Affinity -- Physical -- ctDNA -- miRNA -- Exosomes -- Part 2 -- Biology of CTC -- Dormancy -- Culture -- EMT -- ctDNA and Exosomes -- Cells in circulation with CTC -- Part 3 -- CTC Analysis -- IHC, FISH, and other molecular assays -- Functional characterization -- Advanced microscopy and AI -- Analysis of non-cellular circulating markers -- Part 4 -- Clinical Applications of the Liquid Biopsy -- Early detection and cancer screening -- Prognosis and therapeutic monitoring -- Applications in Clinical Trials -- Applications in Drug Development.

It is well recognized that blood could be the optimal site for evaluating cancer, allowing easy and repeated access for determining prognosis, establishing molecular targets, evaluating the efficacy of therapy, detecting the earliest signs of recurrence, and even detecting cancer at its earliest and most curable stages. The analysis of cancer through blood samples is now known as the liquid biopsy and has been a rich source of research and clinical application. There has been an explosion of interest and progress in liquid biopsy technologies since the first edition of this book. The second edition will expand its focus to now include not only circulating tumor cells (CTC), but also other emerging aspects of the liquid biopsy, including circulating tumor DNA and methylated DNA (ctDNA, ct meDNA), ctRNA, ct miRNA, circulating tumor proteins (and other) biomarkers and circulating tumor derived exosomes (ctExosomes)

ISBN: 9783031229039$q(electronic bk.)

Standard No.: 10.1007/978-3-031-22903-9doiSubjects--Topical Terms:

502015
Cancer cells
--Handbooks, manuals, etc.

LC Class. No.: RC269

Dewey Class. No.: 616.994075

Circulating tumor cellsadvances in liquid biopsy technologies /
LDR:02593nmm a2200349 a 4500 001 648211
003 DE-He213
005 20230801095255.0
006 m d
007 cr nn 008maaau
008 240116s2023 sz s 0 eng d
020 $a 9783031229039$q(electronic bk.)
020 $a 9783031229022$q(paper)
024 7 $a 10.1007/978-3-031-22903-9 $2 doi
035 $a 978-3-031-22903-9
040 $a GP $c GP
041 0 $a eng
050 4 $a RC269
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994075 $2 23
090 $a RC269 $b .C578 2023
245 0 0 $a Circulating tumor cells $h [electronic resource] : $b advances in liquid biopsy technologies / $c edited by Richard J. Cote, Evi Lianidou.
250 $a Second edition.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2023.
300 $a xxi, 668 p. : $b ill., digital ; $c 24 cm.
490 1 $a Current cancer research, $x 2199-2592
505 0 $a Part 1. CTC Technologies -- Affinity -- Physical -- ctDNA -- miRNA -- Exosomes -- Part 2 -- Biology of CTC -- Dormancy -- Culture -- EMT -- ctDNA and Exosomes -- Cells in circulation with CTC -- Part 3 -- CTC Analysis -- IHC, FISH, and other molecular assays -- Functional characterization -- Advanced microscopy and AI -- Analysis of non-cellular circulating markers -- Part 4 -- Clinical Applications of the Liquid Biopsy -- Early detection and cancer screening -- Prognosis and therapeutic monitoring -- Applications in Clinical Trials -- Applications in Drug Development.
520 $a It is well recognized that blood could be the optimal site for evaluating cancer, allowing easy and repeated access for determining prognosis, establishing molecular targets, evaluating the efficacy of therapy, detecting the earliest signs of recurrence, and even detecting cancer at its earliest and most curable stages. The analysis of cancer through blood samples is now known as the liquid biopsy and has been a rich source of research and clinical application. There has been an explosion of interest and progress in liquid biopsy technologies since the first edition of this book. The second edition will expand its focus to now include not only circulating tumor cells (CTC), but also other emerging aspects of the liquid biopsy, including circulating tumor DNA and methylated DNA (ctDNA, ct meDNA), ctRNA, ct miRNA, circulating tumor proteins (and other) biomarkers and circulating tumor derived exosomes (ctExosomes)
650 0 $a Cancer cells $v Handbooks, manuals, etc. $3 502015
650 0 $a Tumors $x Biopsy $v Laboratory manuals. $3 957930
650 1 4 $a Cancer Biology. $3 920982
650 2 4 $a Cancer Therapy. $3 915060
650 2 4 $a Tumour Biomarkers. $3 921175
700 1 $a Cote, Richard J. $3 741047
700 1 $a Lianidou, Evi. $3 957929
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
830 0 $a Current cancer research. $3 558904
856 4 0 $u https://doi.org/10.1007/978-3-031-22903-9
950 $a Biomedical and Life Sciences (SpringerNature-11642)